A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma P van der Bruggen, C Traversari, P Chomez, C Lurquin, E De Plaen, ... Science 254 (5038), 1643-1647, 1991 | 4735 | 1991 |
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase C Uyttenhove, L Pilotte, I Théate, V Stroobant, D Colau, N Parmentier, ... Nature medicine 9 (10), 1269-1274, 2003 | 2761 | 2003 |
Tumor antigens recognized by T lymphocytes T Boon, JC Cerottini, B Van den Eynde, P van der Bruggen, A Van Pel Annual review of immunology 12 (1), 337-365, 1994 | 1664 | 1994 |
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy PG Coulie, BJ Van den Eynde, P Van Der Bruggen, T Boon Nature Reviews Cancer 14 (2), 135-146, 2014 | 1302 | 2014 |
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. B Gaugler, B Van den Eynde, P van der Bruggen, P Romero, JJ Gaforio, ... The Journal of experimental medicine 179 (3), 921-930, 1994 | 990 | 1994 |
Human T cell responses against melanoma T Boon, PG Coulie, BJV Eynde, P Bruggen Annu. Rev. Immunol. 24, 175-208, 2006 | 843 | 2006 |
T cell defined tumor antigens BJ Van den Eynde, P Van Der Bruggen Current opinion in immunology 9 (5), 684-693, 1997 | 814 | 1997 |
A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. B Van den Eynde, O Peeters, O De Backer, B Gaugler, S Lucas, T Boon The Journal of experimental medicine 182 (3), 689-698, 1995 | 747 | 1995 |
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion M Platten, W Wick, BJ Van den Eynde Cancer research 72 (21), 5435-5440, 2012 | 745 | 2012 |
Tumor antigens recognized by T cells T Boon, PG Coulie, B Van den Eynde Immunology today 18 (6), 267-268, 1997 | 716 | 1997 |
Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase L Pilotte, P Larrieu, V Stroobant, D Colau, E Dolušić, R Frédérick, ... Proceedings of the National Academy of Sciences 109 (7), 2497-2502, 2012 | 613 | 2012 |
Tumor‐specific shared antigenic peptides recognized by human T cells P Van Der Bruggen, Y Zhang, P Chaux, V Stroobant, C Panichelli, ... Immunological reviews 188 (1), 51-64, 2002 | 587 | 2002 |
Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 556 | 2014 |
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells S Morel, F Lévy, O Burlet-Schiltz, F Brasseur, M Probst-Kepper, ... Immunity 12 (1), 107-117, 2000 | 537 | 2000 |
An antigenic peptide produced by peptide splicing in the proteasome N Vigneron, V Stroobant, J Chapiro, A Ooms, G Degiovanni, S Morel, ... Science 304 (5670), 587-590, 2004 | 424 | 2004 |
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. B Van den Eynde, B Lethe, A Van Pel, E De Plaen, T Boon The Journal of experimental medicine 173 (6), 1373-1384, 1991 | 413 | 1991 |
Molecular and translational classifications of DAMPs in immunogenic cell death AD Garg, L Galluzzi, L Apetoh, T Baert, RB Birge, BS Pedro, J Manuel, ... Frontiers in immunology 6, 169354, 2015 | 394 | 2015 |
Extensive profiling of the expression of the indoleamine 2, 3-dioxygenase 1 protein in normal and tumoral human tissues I Théate, N van Baren, L Pilotte, P Moulin, P Larrieu, JC Renauld, C Hervé, ... Cancer immunology research 3 (2), 161-172, 2015 | 359 | 2015 |
Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape AD Garg, PG Coulie, BJ Van den Eynde, P Agostinis Trends in immunology 38 (8), 577-593, 2017 | 315 | 2017 |
Rational design of indoleamine 2, 3-dioxygenase inhibitors UF Röhrig, L Awad, A Grosdidier, P Larrieu, V Stroobant, D Colau, ... Journal of medicinal chemistry 53 (3), 1172-1189, 2010 | 313* | 2010 |